Skip to content

Iron therapy in heart failure

Comparative outcomes of intravenous versus oral iron supplementation in acute decompensated heart failure - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/074098
Enrollment
85
Registered
2024-09-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I509- Heart failure, unspecified

Interventions

Intervention1: INTRAVENOUS FCM AND ORAL IRON ADMINISTRATION IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILUE: ONCE THE PATIENTS WITH ADHF IS STABILIZED IN EMERGENCY AND SHIFTED TO MEDICAL WARDS, TH

Sponsors

Government Medical College and Hospital Chandigarh Sector
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Hospitalized patients with acute decompensated heart failure irrespective of LVEF. 2.Patients with iron deficiency. 3.Patients able to complete six minute walk test ( 6MWT). 4.Individuals above 18 years of age.

Exclusion criteria

Exclusion criteria: 1.Serum ferritin concentrations above 400 microgram/dl. 2.Hemoglobin concentration less than 9 gram/dl. 3.Known sensitivity to ferric carboxy maltose. 4.Blood transfusions, intravenous iron therapy, or erythropoetin therapy within 3 months prior to enrolment. 5.Myocardial infarction in last 90 days. 6.Complex cyanotic congenital heart diseases. 7.Severe concomitant conditions like chronic kidney disease,renal dialysis, chronic lung disease chronic liver disease. 8.Hemolytic anemia or myelodysplastic order or abnormalities in iron storage such as hemochromatosis. 9.Recognized hematological, malignant or other active neoplasia. 10.Chemotherapy, radiation, or other immunosuppressive medication within three months of enrolment. 11.Pregnant women. 12.Serious medical conditions that the investigators determine make it impossible for participants to complete the trial.

Design outcomes

Primary

MeasureTime frame
1.Changes in new york heart association (NYHA) functional class at 3 and 6 months. 2.Change in ejection fraction ( by 2d ECHO ) at 6 months. 3.Change in 6MWT distance at 6 months . 4.Change in QOL as assessed by the Minnesota living with heart failure at 6 months . 5.Emergency revisit due to ADHF. 6.Six months readmission due to ADHF. 7.Six month mortality due to ADHF. 8.Six month mortality due to all cardiovascular causes Timepoint: At baseline , 3 months and 6 months

Secondary

MeasureTime frame
NoneTimepoint: Not applicable

Countries

India

Contacts

Public ContactVinod kumar

Government Medical College and Hospital Chandigarh Sector32

drmg1156@gmail.com9646121558

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026